IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.035
EU - Europa 1.033
AS - Asia 343
AF - Africa 20
OC - Oceania 3
SA - Sud America 2
Totale 2.436
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.031
IT - Italia 330
IE - Irlanda 262
SE - Svezia 236
SG - Singapore 161
CN - Cina 127
DE - Germania 39
FR - Francia 30
FI - Finlandia 28
IN - India 26
AT - Austria 22
CI - Costa d'Avorio 18
NL - Olanda 16
CZ - Repubblica Ceca 15
GB - Regno Unito 12
BE - Belgio 10
HK - Hong Kong 6
IR - Iran 6
RU - Federazione Russa 6
TR - Turchia 6
LU - Lussemburgo 5
CH - Svizzera 4
VN - Vietnam 4
AU - Australia 3
CA - Canada 3
MD - Moldavia 3
UA - Ucraina 3
BG - Bulgaria 2
BR - Brasile 2
DK - Danimarca 2
HR - Croazia 2
KR - Corea 2
BS - Bahamas 1
EG - Egitto 1
ES - Italia 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
MK - Macedonia 1
MY - Malesia 1
PH - Filippine 1
PL - Polonia 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.436
Salva come PNG Salva come JPEG
Città #
Chandler 284
Dublin 259
Singapore 101
Ashburn 98
Boardman 94
Shanghai 83
Parma 72
New York 65
Princeton 38
Bologna 30
Chicago 28
Ann Arbor 24
Marseille 24
Milan 24
Helsinki 23
Vienna 22
Verona 19
Abidjan 18
Des Moines 18
Bremen 16
Rome 16
West Jordan 12
Amsterdam 10
Brno 10
Dallas 10
Fremont 10
Santa Clara 10
Beijing 9
Munich 9
Reggio Emilia 9
Sorbolo 9
Trento 9
Wilmington 9
Los Angeles 8
London 7
Pune 7
Houston 6
Louvain-la-Neuve 6
Bolzano 5
Cavriago 5
Istanbul 5
Verdellino 5
Ardea 4
Assago 4
Brussels 4
Dong Ket 4
Florence 4
Hong Kong 4
Kochi 4
Kolkata 4
Modena 4
Olomouc 4
Wayne 4
Aachen 3
Borås 3
Brescia 3
Dearborn 3
Fairfield 3
Jinan 3
Kyiv 3
Lonato 3
Melbourne 3
Norwalk 3
Phoenix 3
Piacenza 3
San Giuliano Milanese 3
Scandiano 3
Tehran 3
Atlanta 2
Ayr 2
Bhubaneswar 2
Central 2
Chisinau 2
Clifton 2
Daejeon 2
Dietikon 2
Falls Church 2
Frankfurt am Main 2
Genoa 2
Hangzhou 2
Hyderabad 2
Maranello 2
Marino 2
Neviano degli Arduini 2
Noviglio 2
Redmond 2
Rio Saliceto 2
Salsomaggiore Terme 2
Seattle 2
Sissa 2
Sofia 2
Sondrio 2
Toronto 2
Treviso 2
Vanløse 2
Vicenza 2
Viggiù 2
Washington 2
Zagreb 2
Zevio 2
Totale 1.679
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 85
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 75
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 73
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 72
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 71
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 69
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 65
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 65
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 63
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 62
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 61
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 58
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 55
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 55
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 53
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 52
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 51
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 50
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 49
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 47
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 47
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 46
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 45
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 45
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 44
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 43
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 42
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 42
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 42
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 42
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 40
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 39
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 39
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 38
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 37
227P Sexual dimorphism in immune profile of early and advanced NSCLC 36
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 35
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 32
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 32
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 31
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 30
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 30
Small cell lung cancer: Novel treatments beyond immunotherapy 29
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 29
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 28
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 27
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 27
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 24
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 24
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 23
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 22
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 21
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 20
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 20
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 19
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 16
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 15
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 13
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 13
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 12
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 11
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 11
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 10
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 10
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 9
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 8
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 8
Totale 2.537
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 4 3 2 0 0 3 0 0
2020/202165 0 0 0 8 5 8 5 8 10 5 2 14
2021/2022276 9 4 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/2025384 63 125 155 41 0 0 0 0 0 0 0 0
Totale 2.537